NHS Scotland, AZ and Scottish universities partner for kidney health research
The collaboration aims to develop new medicines to reduce chronic kidney disease in Scotland
Read More
Tag: NHS Scotland
SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland
The serious, progressive kidney disease affects nearly 850 million people worldwide
Read More
SMC recommends Bayer’s cancer treatments for NHS Scotland use
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read More
NHS in Scotland receives Pfizer’s migraine treatment
Patients living with the debilitating impacts of migraine attacks will be able to access Vydura
Read More
Chiesi’s Trimbow recommended for use within NHS Scotland
The SMC approval brings much-needed boost to asthma sufferers across Scotland
Read More
SMC approves funding for four new medicines on the NHS
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
Read More
SMC kicks off the new year by accepting five new medicines for NHS use
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Read More
Two medicines accepted for use by NHS Scotland
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read More
Waylivra, Tecentriq and more accepted by SMC
Akcea’s Waylivra approved via ultra-orphan pathway
Read More
Darzalex, Ibrance among latest SMC decisions
The Scottish Medicines Consortium (SMC) has announced its latest round of decisions for NHS Scotland, publishing advice accepting three new medicines.
Read More
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read More
SMC accepts four medicines for NHS use
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
